# Cancer Immunotherapy and Biomarkers

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the advances in cancer immunotherapy research, particularly in the context of immune checkpoint blockade targeting PD-1 and PD-L1, the impact of tumor microenvironment, biomarkers for immunotherapy response, T-cell exhaustion, neoantigens, tumor mutational burden, immune-related adverse events, and the exploration of combination therapies. The research also delves into the intricate mechanisms of cancer immunoediting. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t10158 |
| Works | 1,082 |

## Topic papers all

Showing 15 of 1082.

- [Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review](https://scholariq.org/papers/adverse-renal-effects-of-immune-checkpoint-inhibitors-a-narrative-review/)
- [Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer](https://scholariq.org/papers/safety-activity-and-immune-correlates-of-anti-pd-1-antibody-in-cancer/)
- [Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-versus-chemotherapy-for-pd-l1-positive-non-small-cell-lung-cancer/)
- [PD-1 Blockade in Tumors with Mismatch-Repair Deficiency](https://scholariq.org/papers/pd-1-blockade-in-tumors-with-mismatch-repair-deficiency/)
- [Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-advanced-nonsquamous-non-small-cell-lung-cancer/)
- [Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-advanced-squamous-cell-non-small-cell-lung-cancer/)
- [Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer](https://scholariq.org/papers/safety-and-activity-of-anti-pd-l1-antibody-in-patients-with-advanced-cancer/)
- [Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer](https://scholariq.org/papers/mutational-landscape-determines-sensitivity-to-pd-1-blockade-in-non-small-cell/)
- [Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade](https://scholariq.org/papers/mismatch-repair-deficiency-predicts-response-of-solid-tumors-to-pd-1-blockade/)
- [Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-in-metastatic-non-small-cell-lung-cancer/)
- [Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial](https://scholariq.org/papers/pembrolizumab-versus-docetaxel-for-previously-treated-pd-l1-positive-advanced/)
- [The Immune Landscape of Cancer](https://scholariq.org/papers/the-immune-landscape-of-cancer/)
- [Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-for-the-treatment-of-non-small-cell-lung-cancer/)
- [Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/nivolumab-versus-everolimus-in-advanced-renal-cell-carcinoma/)
- [Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors](https://scholariq.org/papers/gut-microbiome-influences-efficacy-of-pd-1-based-immunotherapy-against/)

## Topic primary papers

Showing 15 of 518.

- [Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review](https://scholariq.org/papers/adverse-renal-effects-of-immune-checkpoint-inhibitors-a-narrative-review/)
- [Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer](https://scholariq.org/papers/safety-activity-and-immune-correlates-of-anti-pd-1-antibody-in-cancer/)
- [Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-versus-chemotherapy-for-pd-l1-positive-non-small-cell-lung-cancer/)
- [PD-1 Blockade in Tumors with Mismatch-Repair Deficiency](https://scholariq.org/papers/pd-1-blockade-in-tumors-with-mismatch-repair-deficiency/)
- [Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-advanced-nonsquamous-non-small-cell-lung-cancer/)
- [Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-advanced-squamous-cell-non-small-cell-lung-cancer/)
- [Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer](https://scholariq.org/papers/safety-and-activity-of-anti-pd-l1-antibody-in-patients-with-advanced-cancer/)
- [Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer](https://scholariq.org/papers/mutational-landscape-determines-sensitivity-to-pd-1-blockade-in-non-small-cell/)
- [Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-in-metastatic-non-small-cell-lung-cancer/)
- [Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial](https://scholariq.org/papers/pembrolizumab-versus-docetaxel-for-previously-treated-pd-l1-positive-advanced/)
- [The Immune Landscape of Cancer](https://scholariq.org/papers/the-immune-landscape-of-cancer/)
- [Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-for-the-treatment-of-non-small-cell-lung-cancer/)
- [Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial](https://scholariq.org/papers/atezolizumab-versus-docetaxel-in-patients-with-previously-treated-non-small-cell/)
- [Immune-Related Adverse Events Associated with Immune Checkpoint Blockade](https://scholariq.org/papers/immune-related-adverse-events-associated-with-immune-checkpoint-blockade/)
- [Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer](https://scholariq.org/papers/durvalumab-after-chemoradiotherapy-in-stage-iii-non-small-cell-lung-cancer/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.